Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression

Behavioural Pharmacology

Volumn 28, Issue 1, 2017, Pages 1-8

  Papp, Mariusz ^a   Gruca, Piotr ^a   Lason Tyburkiewicz, Magdalena ^a   Willner, Paul ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Antidepressant; Anxiolytic; Chronic mild stress; Depression; Elevated plus maze; Ketamine; Novel object recognition test; Procognitive; Rat; Sucrose test

Indexed keywords

IMIPRAMINE; KETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NOOTROPIC AGENT;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC MILD STRESS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DISCRIMINATION LEARNING; DRUG ADMINISTRATION; DRUG EFFECT; ELEVATED PLUS MAZE TEST; MALE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; RAT; SUBACUTE DRUG ADMINISTRATION; SUGAR INTAKE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; MAZE TEST; MENTAL STRESS; PSYCHOLOGY; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMIPRAMINE; KETAMINE; MALE; MAZE LEARNING; NOOTROPIC AGENTS; RATS; RATS, WISTAR; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84992160823     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000259     Document Type: Article

References (45)

1. Aanhet Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145.
2. Abdallah CG, Averill LA, Krystal J.H. (2015). Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 1344:66-77.
3. Banasr M, Chowdhury GM, Terwilliger R, Newton S.S., Duman RS, Behar KL, Sanacora G. (2010). Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501-511.
4. 18F-FDG metabolism or tyrosine hydroxylase immunoreactivity in the ventral tegmental area of Wistar rats. Neurochem Res 40:1153-1164.
5. Berman RM, Cappiello A, Anand A., Oren DA, Heninger GR, Charney DS, Krystal J.H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
6. Bersani G, Meco G, Denaro A., Liberati D, Colletti C, Nicolai R., et al. (2013). L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 23:1219-1225.
7. Burgdorf J, Kroes RA, Zhang X.L., Gross AL, Schmidt M, Weiss C, et al (2015). Rapastinel (GLYX-13) has therapeutic potential for the treatment of posttraumatic stress disorder: characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res 294:177-185.
8. Carreno FR, Donegan JJ, Boley A.M., Shah A., DeGuzman M, Frazer A, Lodge D.J. (2016). Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21:1298-1308.
9. Chang CH, Grace A.A. (2014). Amygdala-ventral pallidum pathway decreases dopamine activity after chronic mild stress in rats. Biol Psychiatry 76:223-230.
10. Depoortère R., Dargazanli G, Estenne-Bouhtou G, Coste A., Lanneau C, Desvignes C, et al (2005). Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963-1985.
11. Duman RS, Li N, Liu R.J., Duric V., Aghajanian G. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35-41.
12. Forster GL, Novick AM, Scholl J.L., Watt M.J. (2012). The role of the amygdala in anxiety disorders. In: Ferry B, editor. The amygdala: a discrete multitasking manager. Rijeka, Croatia: InTech.
13. Franceschelli A, Sens J, Herchick S., Thelen C, Pitychoutis P.M. (2015). Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naive and 'depressed' mice exposed to chronic mild stress. Neuroscience 290:49-60.
14. Garcia LS, Comim CM, Valvassori S.S., Réus GZ, Stertz L., Kapczinski F, et al. (2009). Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:450-455.
15. Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A., Paragomi P, Amini H, Afzali M.H. (2014). Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 215:355-361.
16. Gruca P, Lason-Tyburkiewicz M, Papp M. (2011). Evidence for antidepressant- and anxiolytic-like properties of ketamine in animal models. Pharmacol Rep 63:565-566.
17. Holtzheimer PE III, Mayberg HS (2010). Deep brain stimulation for treatment-resistant depression. Am J Psychiatry 167:1437-1444.
18. Jett JD, Boley AM, Girotti M, Shah A., Lodge DJ, Morilak D.A. (2015). Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology (Berl) 232:3123-3133.
19. Klimek V, Papp M. (1994). The effect of MK-801 and imipramine on beta-adrenergic and 5-HT2 receptors in the chronic mild stress model of depression in rats. Pol J Pharmacol 46:67-69.
20. Lara DR, Bisol LW, Munari L.R. (2013). Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 16:2111-2117.
21. Li N, Liu RJ, Dwyer J.M., Banasr M., Lee B, Son H, et al (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754-761.
22. Ma XC, Dang YH, Jia M, Ma R., Wang F, Wu J, et al (2013). Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053.
23. Mahli GS, Byrow Y, Cassidy F., Cipriani A, Demyttenaere K, Frye M.A., et al. (2016). Ketamine: stimulating antidepressant treatment? BMJ Open 2:e5-e9.
24. Nasca C, Xenos D, Barone Y., Caruso A, Scaccianoce S, Matrisciano F., et al. (2013). L-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110:4804-4809.
25. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432.
26. Nikiforuk A, Popik P. (2014). Ketamine prevents stress-induced cognitive inflexibility in rats. Psychoneuroendocrinology 40:119-122.
27. Papp M (2012). Models of affective illness: chronic mild stress in the rat. Curr Protoc Pharmacol 57:5.9.1-5.9.11.
28. Papp M, Moryl E. (1994). Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 263:1-7.
29. Papp M, Moryl E. (1996). Antidepressant-like effects of 1-aminocyclopropane-carboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 316:145-152.
30. Papp M, Gruca P, Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I (2014). Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol 25:567-574.
31. Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P. (2016). Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacol 233:1235-1243.
32. Permoda-Osip A., Kisielewski J, Bartkowska-Sniatkowska A, Rybakowski J.K. (2015). Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry 48:78-79.
33. Preskorn S, Macaluso M, Mehra D.O., Zammit G., Moskal JR, Burch RM, GLYX-13 Clinical Study Group (2015). Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21:140-149.
34. Rajagopal L, Massey BW, Huang M, Oyamada Y., Meltzer H.Y. (2014). The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20:5104-5114.
35. Sun HL, Zhou ZQ, Zhang G.F., Yang C., Wang XM, Shen JC, et al. (2016). Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry 6:e741.
36. Tang J, Xue W, Xia B., Ren L, Tao W, Chen C., et al. (2015). Involvement of normalized NMDA receptor and mTOR-related signaling in rapid anti-depressant effects of Yueju and ketamine on chronically stressed mice. Sci Rep 5:13573.
37. ∗D: implications for clinical practice. Am J Psychiatr 163:28-40.
38. Wheelahan D (2016). Australia's largest trial of ketamine to treat depression begins. Available at: http://newsroom.unsw.edu.au/news/health/australia%E2%80%99s-largest-trial-ketamine-treat-depression-begins. [Accessed 8 September 2016].
39. Willner P (1997). Validity, reliability and utility of the chronic mild stress (CMS) model of depression: a ten-year review and evaluation. Psychopharmacology (Berl) 134:319-329.
40. Willner P (2016). The chronic mild stress (CMS) model of depression: history, evaluation and usage. Neurobiology of Stress. Available at: http://dx.doi.org/10.1016/j.ynstr.2016.08.002.
41. Xu Y, Hackett M, Carter G., Loo C, Gálvez V, Glozier N., et al. (2016). Effects of low-dose andvery low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol 19:pii: pyv124.
42. Zarate CA J.r., Payne JL, Quiroz J, Sporn J., Denicoff KK, Luckenbaugh D, et al. (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161:171-174.
43. Zarate CA J.r., Singh JB, Carlson P.J., Brutsche NE, Ameli R, Luckenbaugh DA, et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
44. Zhang GF, Liu WX, Qiu L.L., Guo J., Wang XM, Sun HL, et al. (2015). Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. Eur Psychiatry 30:504-510.
45. Zhu S, Shi R, Wang J., Wang JF, Li X.M. (2014). Unpredictable chronic mild stress not chronic restraint stress induces depressive behaviours in mice. Neuroreport 25:1151-1155.